Hims & Hers Stock Rockets 40% After Novo Nordisk Obesity Drug Deal
Hims & Hers has struck a landmark agreement with Novo Nordisk to sell its obesity drugs, sending its stock soaring by 40%. This collaboration shift in the healthcare and pharmaceutical markets, with potential ripples extending into the crypto world.



















